CD274 and non-small cell lung carcinoma: However, a phase III trial (CheckMate-26) comparing nivolumab with platinum-baseddoublet chemotherapy as first-line treatment for stage IV, recurrent NSCLC with atleast 1% PD-L1 positive, showed no benefit in the primary endpoint, PFS [median PFS4.2 (CI 3.0–5.6) versus 5.9 (CI 5.4–6.9) months; HR 1.15 (CI0.91–1.45); p = 0.2511].